Should Britain Legalise Weed? The law, the health evidence and what Germany is learning

7 november 2026

The UK still treats cannabis as a Class B drug. But with Germany legalising possession in 2024 and London’s own Drugs Commission publishing a heavyweight review in May 2025, the question isn’t going away: should Britain move from prohibition to a legal, regulated market—or double down on the status quo?

The law now: Class B, 2018 medical exception

Cannabis is a Class B controlled drug under the Misuse of Drugs Act 1971. In England and Wales, the headline penalties are up to five years in prison, an unlimited fine, or both for possession; and up to 14 years for supply or production. Courts sentence within detailed guidelines that scale punishment by harm and culpability. Police responses to simple possession can range from a warning to charge, but the statutory maxima remain stark.

Medical cannabis was carved out in a tightly controlled way on 1 November 2018. From that date, “cannabis‑based products for medicinal use in humans” (CBPMs) could be prescribed by doctors on the GMC specialist register in limited circumstances without a Home Office licence. Most cannabis products remain Schedule 1 under the 2001 Regulations and unlawful to possess, but licensed cannabis medicines and unlicensed CBPMs prescribed by a specialist are allowed.

Recent official stats show cannabis remains by far the most seized drug and the most commonly used illicit drug, with 6.5% of 16–59‑year‑olds and 12.5% of 16–24‑year‑olds in England and Wales reporting use in the year to March 2025 — youth use well below a decade earlier (16.4%).

Cannabis plants — Photo: Alyona Chipchikova / Unsplash

The politics: where parties stood in 2024–26

Government line: “no plans to legalise cannabis,” repeated in written parliamentary answers in 2025.
Labour: The 2024 manifesto did not propose any change to cannabis law, and the government has kept that position.
Conservatives: Oppose liberalisation and favour tougher enforcement.
Liberal Democrats: Their 2024 manifesto backed a legal, regulated cannabis market.
Greens: Their 2024 manifesto backed a public‑health approach and drug‑law reform.
London: The London Drugs Commission (LDC), set up by the Mayor in 2022 and chaired by Lord Charlie Falconer KC, published “The Cannabis Conundrum” on 28 May 2025. It reviewed international evidence and enforcement data, highlighting racial disproportionality in stop and search (Black Londoners more likely to be stopped for suspected cannabis possession but no more likely to be found carrying it), and outlined options including removing cannabis from the Misuse of Drugs Act and creating a regulated market. The report stressed that legalisation doesn’t automatically eliminate the illicit market and set out harm‑reduction and market‑design trade‑offs.

What other countries are doing: Germany, Canada, US states

Germany (2024): The Cannabisgesetz (CanG) made possession of up to 25g by adults legal from 1 April 2024, with home growing up to three plants; non‑profit “cultivation associations” (“cannabis clubs”) followed from 1 July. Advertising is banned; supply to minors remains criminal. An independent evaluation (EKOCAN) runs to 2028. Its first interim report (September 2025) found no clear short‑term rise in use among teenagers or adults and roughly 100,000 fewer cannabis‑related criminal cases in 2024 — but clubs produced under 0.1% of demand. The second interim report (April 2026) found teen use stable to slightly falling, rising health problems among young adults, and a booming online medical‑cannabis market that has become Europe’s largest legal‑commercial cannabis market.
Canada (since 2018): Federal legalisation created a regulated retail market with provincial variation, age limits and packaging rules. Health Canada tracks use every year through its Canadian Cannabis Survey. The big picture is mixed: legal retail has taken a large share of the market but not all of it, youth trends vary by measure and year, and enforcement has shifted towards illicit retail and impaired driving.
US states: The research is nuanced and still evolving. Some peer‑reviewed studies link recreational legalisation to higher traffic fatality rates, while teen “any use” has broadly held steady or fallen since the pandemic. Bottom line: legalisation hasn’t clearly driven a long‑term spike in teen experimentation, but heavy adult use and road safety are credible concerns.

Cannabis in a UK context — Photo: Cosmin Ursea / Unsplash

The health evidence: harms are real, risks are dose‑ and age‑related

NHS guidance flags established risks: acute intoxication impairs reaction time and driving; regular use can worsen anxiety, depression and is linked to dependence; and there is evidence that frequent/high‑THC use increases the risk of psychotic illness in susceptible people. UK psychiatric bodies and recent research echo this, warning that earlier onset, higher THC, and frequent use elevate psychosis risk, and that continued cannabis use after a psychotic episode worsens relapse and outcomes. Cannabis is also one of the most common reasons people seek drug treatment. None of this negates the separate, strictly‑regulated medical role for some cannabinoid products.

The latest UK developments (2025–26)

London Drugs Commission (28 May 2025): published “The Cannabis Conundrum,” spotlighting enforcement disparities, cataloguing international models, and setting out evidence‑based options rather than a single blueprint. The Home Office said national drug law is unchanged.
Central government: repeated in Parliament that it has no plans to legalise cannabis, while making narrow changes to industrial hemp licensing. No wider reform has been proposed as of November 2026.
Policing/enforcement data: Cannabis remains the most seized drug; cannabis seizures in England and Wales rose 28% to 194,682 in the year to March 2025, and Border Force seized a record 127 tonnes of herbal cannabis.

Where this leaves the UK

The legal status quo is clear: cannabis is illegal to possess, supply or grow without a specific medical route—and the government isn’t planning to change that. But the ground is moving internationally. Germany’s two‑pillar approach provides a European case study deliberately avoiding full commercial retail, while Canada and US states offer longer‑run evidence on markets, youth trends, impaired driving, dependence and illicit‑market persistence. UK health guidance is consistent: the harms are real and grow with earlier, heavier, higher‑THC use.

If the UK ever chose to legalise, the details would matter more than the slogan—age limits, product caps, marketing bans, price/tax, outlet density, impaired‑driving rules, social‑equity licensing and funding for treatment and prevention. The London Drugs Commission has given policymakers a thick menu of options and trade‑offs to interrogate. For now, Westminster says no.

Key facts

UK law today: Cannabis is Class B. Max penalties: 5 years for possession; 14 for supply/production; unlimited fines possible. Medical cannabis prescriptions by specialists have been legal since 1 November 2018 under strict rules. (as at 7 Nov 2026)
Use trends: 6.5% of 16–59s and 12.5% of 16–24s used cannabis in the year to March 2025 (ONS, published December 2025).
Germany 2024: Adults may possess up to 25g and grow 3 plants; “cannabis clubs” from July 2024; second EKOCAN interim report published April 2026. (law effective 1 Apr and 1 Jul 2024; evaluation timeline set 2024)
UK politics: The government says it has “no plans to legalise cannabis”; some smaller parties back reform.
Policing: Cannabis was the most seized drug; seizures up 28% in FY ending 2025. (published 2026)

What this means for you

Possession remains a criminal offence in the UK. Don’t assume “it’s basically legal”—it isn’t, and penalties can escalate.
A genuine medical route exists but is narrow: only specialist doctors can prescribe CBPMs and most products remain controlled. Consult your clinician, not Instagram.
If you travel: Germany’s rules apply within Germany only; bringing cannabis back to the UK is a serious offence.
Health: Risk rises with earlier start, higher THC and frequent use. Do not drive high. If you’re experiencing anxiety, paranoia or psychotic symptoms, seek help.

Film treatment

Opening montage: Berlin on 1 April 2024—celebrations vs police briefings; cut to London estate stop‑and‑search sequence; graphic overlays of “25g/3 plants” vs “Class B/5 years”.
Interview set 1: Lord Charlie Falconer KC and UCL researchers unpack the London Drugs Commission findings; counterpoint with the government’s “no plans” position.
Interview set 2: NHS psychiatrist and an A&E consultant on psychosis, cannabis hyperemesis syndrome and impaired‑driving cases; then a medical‑cannabis patient discussing access barriers.
Data visual: UK adult use trend (ONS), Germany’s legal timeline, and a US chart on traffic fatalities post‑legalisation—“policy design matters”.
Street‑level: Licensed Canadian retailer vs an illicit market runner; how pricing, product strength, and ID checks shape who buys what.

Research limits

Youth use and harm trends are sensitive to survey design and pandemic‑era shocks; international comparisons aren’t like‑for‑like.
Germany’s reform is still young; EKOCAN’s interim findings are explicitly provisional, and the full evaluation runs to 2028.
UK enforcement data signal activity (e.g., seizures) but don’t precisely map consumption or market size.

Sources

Photos: Rick Proctor; Alyona Chipchikova; Cosmin Ursea (all via Unsplash, Unsplash License).

Also on TRVTH Truths.

Shop the message: wear what you stand for — browse the TRVTH collection.

Tillbaka till blogg

Din varukorg är tom

Din varukorg

Beräknad totalsumma